Potassium Channel Subfamily K, Member 2 (KCNK2)

[Edit]

K2p2.1; TPKC1; TREK; TREK-1; TREK1; hTREK-1c; hTREK-1e; Outward rectifying potassium channel protein TREK-1; Two pore domain potassium channel TREK-1

Potassium Channel Subfamily K, Member 2 (KCNK2)
TREK1 is a 2-pore-domain background potassium channel expressed throughout the central nervous system. It is opened by polyunsaturated fatty acids, lysophospholipids, and volatile anesthetics, and it is inhibited by neurotransmitters that increase intracellular cAMP or activate the Gq signaling pathway.
The Trek cDNA encodes a 370-amino acid polypeptide. In situ hybridization of mouse brain revealed that its expression is widespread.Trek1 was necessary but not sufficient to provide mechanical and chemical sensitivities. Trek1 truncation mutants lacking 2 C-terminal protein kinase A consensus phosphorylation sites were insensitive to cAMP and serotonin, suggesting that phosphorylation may be involved in downmodulation of Trek1 by cAMP.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Potassium Channel Subfamily K, Member 2 (KCNK2) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Potassium Channel Subfamily K, Member 2 (KCNK2) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Potassium Channel Subfamily K, Member 2 (KCNK2) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Potassium Channel Subfamily K, Member 2 (KCNK2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Potassium Channel Subfamily K, Member 2 (KCNK2) ELISA Kit Customized Service Offer

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Potassium Channel Subfamily K, Member 2 (KCNK2) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Potassium Channel Subfamily K, Member 2 (KCNK2) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Potassium Channel Subfamily K, Member 2 (KCNK2) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Potassium Channel Subfamily K, Member 2 (KCNK2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Potassium Channel Subfamily K, Member 2 (KCNK2) ELISA Kit Customized Service Offer

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Potassium Channel Subfamily K, Member 2 (KCNK2) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Potassium Channel Subfamily K, Member 2 (KCNK2) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Potassium Channel Subfamily K, Member 2 (KCNK2) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Potassium Channel Subfamily K, Member 2 (KCNK2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Potassium Channel Subfamily K, Member 2 (KCNK2) ELISA Kit Customized Service Offer
  1. "Inhalational anesthetics activate two-pore-domain background K+ channels."Nat. Neurosci. 2:422-426(1999) [PubMed] [Europe PMC] [Abstract]
  2. "Cloning, localisation and functional expression of the human orthologue of the TREK-1 potassium channel."Pflugers Arch. 439:714-722(2000) [PubMed] [Europe PMC] [Abstract]
  3. "A splice variant of the two-pore domain potassium channel TREK-1 with only one pore domain reduces the surface expression of full-length TREK-1 channels."Pflugers Arch. 466:1559-1570(2014) [PubMed] [Europe PMC] [Abstract]
  4. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  5. "The DNA sequence and biological annotation of human chromosome 1." Nature 441:315-321(2006) [PubMed] [Europe PMC] [Abstract]
  6. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  7. "KCNK2: reversible conversion of a hippocampal potassium leak into a voltage-dependent channel."Nat. Neurosci. 4:486-491(2001) [PubMed] [Europe PMC] [Abstract]